Status:
COMPLETED
Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
Lead Sponsor:
Centre Oscar Lambret
Conditions:
Cancer
Solid Tumor
Eligibility:
All Genders
18+ years
Brief Summary
This study describes the elevation of CPK in patient treated for solid tumors by TKI
Eligibility Criteria
Inclusion
- Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week
- Patient examined AND with a routine blood test planned
- Patient informed of procedure for the study who was not opposed to it
Exclusion
- Patient treated for malignant hemopathy
- Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
- Patients with no routine blood laboratory tests planned
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT01248429
Start Date
November 1 2010
End Date
February 1 2011
Last Update
June 7 2012
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Paul Papin
Angers, France, 49000
2
Hôpital Jean Minjoz
Besançon, France, 25030
3
CHU Bordeaux
Bordeaux, France, 33076
4
Institut Bergonié
Bordeaux, France, 33076